Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01222975
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : October 18, 2010
Information provided by:
Ranbaxy Inc.

October 15, 2010
October 18, 2010
October 18, 2010
October 2004
October 2004   (Final data collection date for primary outcome measure)
Bioequivalence evaluation of Risperidone 1 mg Orally-disintegrating tablets
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions
Single Dose Two-way Crossover Fasted Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers
The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fasted conditions.
A single dose two way crossover bioequivalence study in 44 normal healthy males and females was utilized to evaluate the pharmacokinetics and bioequivalence of Risperidone ODT (orally dissolving tablet) formulations. The test product was a 1 mg ODT tablet formulation of Risperidone manufactured by Ranbaxy Laboratories Ltd. The reference product was commercially available Risperidone 1 mg ODT tablets (Risperdal®), Janssen Pharmaceutica Products, LP. Each single oral dose (1 mg) will be administered orally as a 1 mg tablet. Blood samples were collected at intervals over a 72-hour period after medication administration. There was a washout period of 14 days between the two periods of the study.
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Drug: Risperidone
orally disintegrating tablets
  • Experimental: 1
    Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
    Intervention: Drug: Risperidone
  • Active Comparator: 2
    Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
    Intervention: Drug: Risperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2004
October 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy subjects at least 18 years of age
  2. Informed of the nature of the study and given written informed consent
  3. Have a body weight within 15% of the appropriate range as defined in the 1983 Metropolitan Life Company tables weighing at least 110 pounds

Exclusion Criteria:

  1. Hypersensitivity to risperidone (Risperdal®)
  2. Any history of a clinical condition that might affect drug absorption, metabolism or excretion
  3. Recent history (within one year) of mental illness, drug addiction, drug abuse or alcoholism
  4. Donation of greater than 500 mg of blood in the past 4 weeks prior to study dosing or difficulty in donating blood
  5. Received an investigational drug within the 4 weeks prior to study dosing
  6. Currently taking any prescription medication, except for oral contraceptives, within the 7 days prior to the study dosing or over the counter medication within 3 days of study dosing. This prohibition does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications as judged by the attending physician
  7. Regular smoking or more than 5 cigarettes daily or the daily use of nicotine-containing products beginning 3 months before the study medication administration through the final evaluation
  8. If female the subject is lactating or has a positive pregnancy test at screening and prior to each of the treatment periods. Females of child-bearing potential must use a medically acceptable method of contraception throughout the study period and for one week after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/ or her partner are: oral contraceptives, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence. Females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication
  9. Alcohol, grapefruit beverages or foods or caffeine beverages or foods beginning 1 days before each study medication administration through each study confinement period. Such restricted items include coffee, tea, iced tea, coke®, Pepsi®, mountain dew®, chocolate, brownies, etc.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Dr. Tausif Monif, Ranbaxy Research Laboratories
Ranbaxy Laboratories Limited
Not Provided
Not Provided
Ranbaxy Inc.
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP